Industrial Distribution

Shenzhen·Chengdu·Beijing·Shanghai four-in-one modern biomedicine group company





Beijing Clinical Research Department, responsible for the formulation and implementation of clinical study protocols for new drugs, is an important technical center that contributes to the approval of new drug registration.

Chengdu Chipscreen Pharmaceutical Co., Ltd., located in Chengdu High-tech Zone, is the production base of Chiglitazar Sodium and Chiauranib, and the regional R&D center and regional headquarters of innovative drugs.

Shanghai Business Center, the marketing center of tumor products, the marketing center of metabolic disease products, and the product strategy and business development center.

Shenzhen Chipscreen Biosciences, Ltd. (Group Headquarters), located in Nanshan High-tech Zone, Shenzhen, is the innovative drug development and management center of the Company. Shenzhen Chipscreen Pharmaceutical Co., Ltd., located in Pingshan District, Shenzhen, is the production base of Chidamide.

Chengdu Chipscreen Pharmaceutical Co., Ltd

Chengdu Chipscreen Pharmaceutical Co., Ltd

(hereinafter referred to as "Chengdu Chipscreen Pharmaceutical"), established on April 28, 2014, is a wholly-owned subsidiary of Shenzhen Chipscreen Biosciences Co., Ltd. Chengdu Chipscreen Pharmaceutical is composed of two areas, namely, the "Innovative Drug Production Base" and the "Innovative Drug R&D Center and Regional Headquarters".

Innovative Drug Production Base:

located at No. 298 Kangqiang 1st Road, West High-tech Zone, Chengdu, covers an area of 100 mu (equivalent to about 66,667 square meters). Facilities here include oncology/non-oncology API workshops and oncology/non-oncology oral solid preparation workshops, which are designed in accordance with GMP standards published in the US, EU and China. In order to satisfy the needs for pilot scale tests of innovative drugs, preparation of clinical samples and production of marketed products, the construction of new facilities, such as pilot workshops for oncology/non-oncology APIs, multi-functional oral solid preparations and injections workshops, and antibody API manufacturing workshops, are under planning.

Innovative Drug R&D Center and Regional Headquarters:

located in Xinchuan Science and Technology Park, South High-tech Zone, cover an area of 25 mu (equivalent to 16,667 square meters). With the main body of the building already been roofed, this construction project is expected to be completed and put into use in 2020,which is expected to promote the product chain and give supports to clinical studies together with the Research & Early Development Center (Shenzhen) in a manner that they effectively complement each other in the research advantages. The Innovative Drug R&D Center and Regional Headquarters will play an important role in the R&D of the Group and make scientific and strategic contributions to the Group in the research and development of new drugs.